Clinical trial register

Trials are recorded only where the registry identifier has been verified against the registry record. Outcomes are reported as the trial reported them and attributed to that trial. They are not statements about what a compound does for a person.

Trial	Compound	Phase	Enrolment	Status	Peer reviewed
STEP 1	Semaglutide	3	1961	reported	Published
SUSTAIN-6	Semaglutide	3	3297	reported	Published
SURMOUNT-1	Tirzepatide	3	2539	reported	Published
SURPASS-2	Tirzepatide	3	1879	reported	Published
ATTAIN-1	Orforglipron	3	3127	reported	Published
ATTAIN-2	Orforglipron	3	1613	reported	Published
ACHIEVE-1	Orforglipron	3	559	reported	Topline only
Phase 2 obesity trial	Retatrutide	2	338	reported	Published
TRIUMPH-1	Retatrutide	3	2335	reported	Topline only
TRIUMPH-2	Retatrutide	3	1152	reported	Topline only
TRIUMPH-3	Retatrutide	3	1946	reported	Topline only
TRIUMPH-4	Retatrutide	3	445	reported	Topline only
TRANSCEND-T2D-1	Retatrutide	3	537	reported	Published

Back to the knowledge base

Scope of this reference

This knowledge base is scientific and regulatory reference material for businesses. It is not medical advice, not a recommendation, and not product promotion. Regulatory classification differs by jurisdiction, by form and by route of administration, and a statement recorded for one territory does not describe the position in another.

HelixEVO does not supply medicinal products for human administration. Material is supplied to businesses for research and manufacturing purposes only. Where a compound holds no marketing authorisation, human administration outside an authorised clinical trial is not a lawful supply route.

Every regulatory and analytical statement carries its source and the date it was last verified. Where a value could not be established from a primary source it is recorded as unverified rather than estimated.